A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy.

导出原文传递

翻译打印收藏纠错

作者： Frank A,Vicini ^[1] ; G Bruce,Mann ^[2] ; Chirag,Shah ^[3] ; Sheila,Weinmann ^[4] ; Michael C,Leo ^[4] ; Pat,Whitworth ^[5] ; Rachel,Rabinovitch ^[6] ; Mylin A,Torres ^[7] ; Julie A,Margenthaler ^[8] ; David,Dabbs ^[9] ; Jess,Savala ^[9] ; Steven C,Shivers ^[9] ; Karuna,Mittal ^[9] ; Fredrik,Wärnberg ^[10] ; Troy,Bremer ^[9]

作者单位： GenesisCare, Farmington Hills, Michigan. Electronic address: frank.vicini2@usa.genesiscare.com. ^[1] Department of Surgery, The University of Melbourne, Melbourne, Australia. ^[2] Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. ^[3] Center for Health Research, Kaiser Permanente Northwest Research Center, Portland, Oregon. ^[4] Nashville Breast Center, Nashville, Tennessee. ^[5] Department of Radiation Oncology, University of Colorado, Colorado Springs, Colorado. ^[6] Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. ^[7] Department of General Surgery, Section of Surgical Oncology, Washington University School of Medicine, St Louis, Missouri. ^[8] PreludeDx, Laguna Hills, California. ^[9] Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ^[10]